✦ LIBER ✦

483 PREVALENCE OF ELEVATED C-REACTIVE PROTEIN LEVELS IN A PRIMARY CVD PREVENTION POPULATION IN EUROPE: THE EURIKA STUDY

✍ Scribed by Halcox, J.; Banegas, J.R.; Dallongeville, J.; Backer, G.D.; Guallar, E.; Massó-González, E.L.; Perk, J.; Rodriguez Artalejo, F.; Steg, P.G.; Tubach, F.; Borghi, C.

Book ID: 118639490
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 42 KB
Volume: 12
Category: Article
ISSN: 1567-5688
DOI: 10.1016/s1567-5688(11)70484-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Primary prevention of vascular events in

Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study

✍ Fonseca, Francisco AH; Izar, Maria Cristina O 📂 Article 📅 2009 🏛 Expert Reviews 🌐 English ⚖ 630 KB

Prevalence of Low Low-Density Lipoprotei

Prevalence of Low Low-Density Lipoprotein Cholesterol With Elevated High Sensitivity C-Reactive Protein in the U.S.: Implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) Study

✍ Erin D. Michos; Roger S. Blumenthal 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 196 KB

Rosuvastatin in the Primary Prevention o

Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial*

✍ Ridker, P. M 📂 Article 📅 2003 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 427 KB

Baseline Characteristics of Participants

Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

✍ Paul M. Ridker; Francisco A.H. Fonseca; Jacques Genest; Antonio M. Gotto; John J 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 119 KB

Elevated Alanine Aminotransferase Predic

Elevated Alanine Aminotransferase Predicts New-Onset Type 2 Diabetes Independently of Classical Risk Factors, Metabolic Syndrome, and C-Reactive Protein in the West of Scotland Coronary Prevention Study

✍ Sattar, N.; Scherbakova, O.; Ford, I.; O'Reilly, D. St. J.; Stanley, A.; Forrest 📂 Article 📅 2004 🏛 American Diabetes Association 🌐 English ⚖ 108 KB

Why not use the HbA1c as a criterion of

Why not use the HbA1c as a criterion of dysglycemia in the new definition of the metabolic syndrome? Impact of the new criteria in the prevalence of the metabolic syndrome in a Mediterranean urban population from Southern Europe (IMAP study. Multidisciplinary intervention in primary care)

✍ M. Rosa Bernal-Lopez; Aurora Villalobos-Sanchez; Jose Mancera-Romero; Sergio Jan 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 237 KB